An Antithrombin III product containing biologically active hepatocyte growth factor may be beneficial in deep ulcer infections

Cytokine

Volumn 60, Issue 2, 2012, Pages 478-486

  Lönn, Johanna ^a,b   Almroth, Gabriel ^c   Brudin, Lars ^c   Nayeri, Fariba ^a,d  

^a PEAS Institute   (Sweden)

^b ÖREBRO UNIVERSITY   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Antithrombin III; Biological activity; Deep ulcer infection; Hepatocyte growth factor

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; ANTITHROMBIN III; AT III BAXTER; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; CLAVULANIC ACID; CLINDAMYCIN; COLISTIN; COTRIMOXAZOLE; ERYTHROMYCIN; FUSIDIC ACID; MEROPENEM; METRONIDAZOLE; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; RECOMBINANT ANTITHROMBIN III; SCATTER FACTOR; THROMBHIBIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANIMAL CELL; ARTICLE; BELOW KNEE AMPUTATION; BINDING AFFINITY; BIOLOGICAL ACTIVITY; BLINDNESS; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP ULCER INFECTION; DIABETIC FOOT; DRUG EFFICACY; EAR INFECTION; ENDOCARDITIS; FEMALE; HEART FAILURE; HEMOLYTIC UREMIC SYNDROME; HUMAN; IN VITRO STUDY; KIDNEY FAILURE; LIGAND BINDING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; REGENERATIVE ABILITY; SEPTICEMIA; SKIN ULCER; TISSUE REGENERATION; ULCER HEALING; WOUND HEALING;

AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODY SPECIFICITY; ANTITHROMBIN III; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELLS, CULTURED; CRITICAL ILLNESS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; LIGANDS; MALE; MICE; MIDDLE AGED; SURFACE PLASMON RESONANCE; ULCER; YOUNG ADULT;

EID: 84866762818     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.05.023     Document Type: Article

References (27)

1. Chen L., Wen Y.M. The role of bacterial biofilm in persistent infections and control strategies. Int J Oral Sci 2011, 3:66-73.
2. Alison M.R., Nicholson L.J., Lin W.R. Chronic inflammation and hepatocellular carcinoma. Recent Results Cancer Res 2011, 185:135-148.
3. Holdaas H., Holme I., Schmieder R.E., Jardine A.G., Zannad F., Norby G.E., et al. Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol 2011, 22:1335-1341.
4. Marteau P., Chaput U. Bacteria as trigger for chronic gastrointestinal disorders. Dig Dis 2011, 29:166-171.
5. Calvaruso V., Craxì A. Fibrosis in chronic viral hepatitis. Best Pract Res Clin Gastroenterol 2011, 25:219-230.
6. Rogler G. Interaction between susceptibility and environment: examples from the digestive tract. Dig Dis 2011, 29:136-143.
7. Straub R.H., Buttgereit F., Cutolo M. Alterations of the hypothalamic-pituitary-adrenal axis in systemic immune diseases - a role for misguided energy regulation. Clin Exp Rheumatol 2011, 29:S23-S31.
8. Nakamura T., Sakai K., Matsumoto K. Hepatocyte growth factor twenty years on: much more than a growth factor. J Gastroenterol Hepatol 2011, 26(Suppl. 1):188-202.
9. Stella M.C., Comoglio P.M. HGF: a multifunctional growth factor controlling cell scattering. Int J Biochem Cell Biol 1999, 31:1357-1362.
10. Nayeri F., Nilsson I., Skude G., Brudin L., Söderström C. Hepatocyte growth factor (HGF) in patients with pneumonia: a comparison between survivors and non-survivors. Scand J Infect Dis 1998, 30:405-409.
11. Nayeri F., Olsson H., Peterson C., Sundqvist T. Hepatocyte growth factor; expression, concentration and biological activity in chronic leg ulcers. J Dermatol Sci 2005, 37:75-85.
12. Nayeri F., Forsberg P., Sundqvist T., Olsson H., Peterson C., Söderström C., et al. Hepatocyte growth factor in chronic leg ulcers - no biological activity - no improvement. J Dermatol Sci 2005, 39:62-64.
13. Nayeri F., Strömberg T., Larsson M., Brudin L., Söderström C., Forsberg P. Hepatocyte growth factor may accelerate healing in chronic leg ulcers: a pilot study. J Dermatolog Treat 2002, 13:81-86.
14. Moubarak P., Zilker S., Wolf H., Hofner B., Kneib T., Küchenhoff H., et al. Activity-guided Antithrombin III therapy in severe surgical sepsis: efficacy and safety according to a retrospective data analysis. Shock 2008, 30:634-641.
15. Afshari A., Wetterslev J., Brok J., Møller A.M. Antithrombin III for critically ill patients. Cochrane Database Syst Rev 2008, CD005370.
16. Warren B.L., Eid A., Singer P., Pillay S.S., Carl P., Novak I., et al. Caring for the critically ill patient. High-dose Antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001, 286:1869-1878.
17. Nayeri F., Holmgren-Pettersson K., Perskvist N., Forsberg P., Peterson C., Sundqvist T. An in vitro model for assessment of the biological activity of hepatocyte growth factor. Growth Factors 2007, 25:33-40.
18. Nayeri F., Nayeri T., Aili D., Brudin L., Liedberg B. Clinical impact of real-time evaluation of the biological activity and degradation of hepatocyte growth factor. Growth Factors 2008, 26:163-171.
19. Jonsson U., Fagerstam L., Lofas S., Stenberg E., Karlsson R., Frostell A., et al. Introducing a biosensor based technology for real-time biospecific interaction analysis. Annales de biologie clinique 1993, 51:19-26.
20. Nayeri F., Xu J., Abdiu A., Nayeri T., Aili D., Liedberg B., et al. Autocrine production of biologically active hepatocyte growth factor (HGF) by injured human skin. J Dermatol Sci 2006, 43:49-56.
21. Birchmeier W., Brinkmann V., Niemann C., Meiners S., DiCesare S., Naundorf H., et al. Role of HGF/SF and c-Met in morphogenesis and metastasis of epithelial cells. Ciba Found Symp 1997, 212:230-240. discussion 40-6.
22. Ammons C.B. Anti-biofilm strategies and the need for innovations in wound care. Recent Pat Antiinfect Drug Discov 2010, 5:10-17.
23. Petersen P.E., Ogawa H. Strengthening the prevention of periodontal disease: the WHO approach. J Periodontol 2005, 76:2187-2193.
24. Nakayama K. Porphyromonas gingivalis cell-induced hemagglutination and platelet aggregation. Periodontology 2000, 2010(54):45-52.
25. Matsumoto K., Nakamura T. Hepatocyte growth factor (HGF) as a tissue organizer for organogenesis and regeneration. Biochem Biophys Res Commun 1997, 239:639-644.
26. Pietrapiana D., Sala M., Prat M., Sinigaglia F. Met identification on human platelets: role of hepatocyte growth factor in the modulation of platelet activation. FEBS Lett 2005, 579:4550-4554.
27. Kamimoto M., Mizuno S., Matsumoto K., Nakamura T. Hepatocyte growth factor prevents multiple organ injuries in endotoxemic mice through a heme oxygenase-1-dependent mechanism. Biochem Biophys Res Commun 2009, 380:333-337.